Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 5/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.42 |
| ▸ | VCP | P55072 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544294 | 1.00 | PDE4D (0.47) | PDE4DRAB9ANPC1AKR1C3AKR1C1 | |
| Bicarbonate SCHEMBL19583807 | 0.90 | POLB (0.41) | PDE4DCYP3A4TSHRPOLBGAA | |
| SCHEMBL17449295 | 0.84 | MEN1 (0.42) | RAB9ANPC1CYP3A4TSHRHPGD | |
| SCHEMBL31108761 | 0.84 | MEN1 (0.42) | RAB9ANPC1CYP3A4TSHRHPGD | |
| Formaldehyde SCHEMBL28205505 | 0.83 | TSHR (0.41) | RAB9ANPC1CYP3A4TSHRPOLB | |
| SCHEMBL2545864 | 0.82 | HPGD (0.44) | VCPGAAHPGD | |
| SCHEMBL12261628 | 0.82 | SMN1; SMN2 (0.45) | RAB9ALMNAGAAHPGD | |
| SCHEMBL2545867 | 0.82 | HPGD (0.44) | VCPGAAHPGD | |
| SCHEMBL2544977 | 0.81 | PDE4D (0.47) | PDE4DRAB9ANPC1AKR1C3AKR1C1 | |
| SCHEMBL2544973 | 0.81 | PDE4D (0.47) | PDE4DRAB9ANPC1AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560975-B1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-06-17 | — | — | EP | disclosed |
| EP-2560975-B1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-06-17 | — | — | EP | disclosed |
| US-8492376-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492376-B2 | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | HOFFMANN-LA ROCHE INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2560975-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011131596-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131596-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | HOFFMANN-LA ROCHE, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263578-A1 | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES | AVPR1A, AVPR1B, OXTR | PDE4D 2975/4885RAB9A 634/4885NPC1 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.